Cell populations in the anorectal transition zone with tissue regenerative capacity, and methods for isolation and use thereof
AssigneeCurileum Discovery Ltd
InventorsJeffrey G. Moore, Priti Kalra
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions of anorectal transition zone stem cells, including multipotent and progenitor cells, to treat endodermal disease. Also provided are cellular compositions of the anorectal transition zone stem cells, including multipotent and progenitor cells, in a pharmaceutically acceptable carrier.
Claims45
A cellular composition for use in cell transplantation to treat a damaged or dysfunctional endodermal tissue in a subject, comprising:
- a mixed population of ATZ cells comprising multipotent ATZ stem cells and endodermal progenitor ATZ cells in a pharmaceutically-acceptable carrier or exogenous biocompatible scaffold.
A method of producing a cellular composition for use in cell transplantation to treat a damaged or dysfunctional endodermal tissue in a subject, comprising:
- (a) obtaining a sample of ATZ cells that are autologous or allogeneic to the subject;
- (b) isolating a mixed population of ATZ cells comprising multipotent ATZ stem cells and endodermal progenitor ATZ cells from the sample;
- and
- (c) expanding the multipotent ATZ stem cells in a minimal growth medium (MGM).
A method treating damaged or dysfunctional endodermal tissue in a subject, comprising:
- (a) obtaining a sample of ATZ cells that are autologous or allogeneic to the subject;
- (b) isolating a mixed population of ATZ cells comprising multipotent ATZ stem cells and endodermal progenitor ATZ cells from the sample;
- (c) expanding the multipotent ATZ stem cells within the mixed population in a minimal growth medium (MGM), and.
- (d) introducing a therapeutically effective amount of the multipotent ATZ stem cells within the mixed population into the damaged or dysfunctional tissue in the subject.
A method treating damaged or dysfunctional endodermal tissue in a subject, comprising:
- (a) obtaining a sample of ATZ cells that are autologous or allogeneic to the subject;
- (b) isolating a mixed population of ATZ cells comprising multipotent ATZ stem cells and endodermal progenitor ATZ cells from the sample;
- (c) expanding the multipotent ATZ stem cells within the mixed population by culturing the mixed population in a minimal growth medium (MGM),
- (d) culturing the mixed population in an endodermal lineage-specific medium (LSM) to promote at least partial differentiation of multipotent ATZ stem cells within the mixed population to produce an expanded population of endodermal progenitor ATZ cells within the mixed population;
- and
- (e) introducing a therapeutically effective amount of the multipotent ATZ stem cells and endodermal progenitor ATZ cells into the damaged or dysfunctional tissue in the subject.
A cellular composition, comprising:
- a mixed population of ATZ cells comprising multipotent ATZ stem cells and endodermal progenitor ATZ cells in a pharmaceutically-acceptable carrier or exogenous biocompatible scaffold.
A cellular composition for use in a method of treating damaged or dysfunctional endodermal tissue, in a subject, wherein:
- the composition comprises isolated ATZ cells and/or ATZ-derived organoid cells.
Dependencies are inferred from the claim text.